Karel Everaert1, Francois Hervé1, Ruud Bosch2, Roger Dmochowski3, Marcus Drake4, Hashim Hashim4, Christopher Chapple5, Philip Van Kerrebroeck6, Sherif Mourad7, Paul Abrams4, Alan Wein8. 1. Urology Department, Ghent University Hospital, Ghent, Belgium. 2. Urology Department, UMC Utrecht, Utrecht, The Netherlands. 3. Urology Department, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Bristol Urological Institute, University of Bristol, Bristol, United Kingdom. 5. Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Sheffield, United Kingdom. 6. Urology Department, Maastricht University Medical Center, Maastricht, The Netherlands. 7. Urology Department, Ain Shams University, Cairo, Egypt. 8. Urology Department, University of Philadelphia, Philadelphia, Pennsylvania.
Abstract
INTRODUCTION: Patients with nocturia have to face many hurdles before being diagnosed and treated properly. The aim of this paper is to: summarize the nocturia patient pathway, explore how nocturia is diagnosed and treated in the real world and use the Delphi method to develop a practical algorithm with a focus on what steps need to be taken before prescribing desmopressin. METHODS: Evidence comes from existing guidelines (Google, PubMed), International Consultation on Incontinence-Research Society (ICI-RS) 2017, prescribing information and a Delphi panel (3 rounds). The International Continence Society initiated this study, the authors represent the ICI-RS, European Association of Urology, and Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU). RESULTS: Diagnostic packages: consensus on, history taking for all causalities, intake diary (fluid, food) and bladder diary, not for its duration. Pelvic (women) or rectal (men) examination, prostate-specific antigen, serum sodium check (SSC), renal function, endocrine screening: when judged necessary. Timing or empty stomach when SSC is not important. Therapeutic packages: the safe candidates for desmopressin can be phenotyped as no polydipsia, heart/kidney failure, severe leg edema or obstructive sleep apnea syndrome. Lifestyle interventions may be useful. Initiating desmopressin: risk management consensus on three clinical pictures. Follow-up of desmopressin therapy: there was consensus on SSC day 3 to 7, and at 1 month. Stop therapy if SSC is <130 mmol/L regardless of symptoms. Stop if SSC is 130 to 135 mmol/L with symptoms of hyponatremia. CONCLUSION: A summary of the nocturia patient pathway across different medical specialists is useful in the visualization and phenotyping of patients for diagnosis and therapy. By summarizing basic knowledge of desmopressin, we aim to ease its initiation and shorten the patient journey for nocturia.
INTRODUCTION:Patients with nocturia have to face many hurdles before being diagnosed and treated properly. The aim of this paper is to: summarize the nocturiapatient pathway, explore how nocturia is diagnosed and treated in the real world and use the Delphi method to develop a practical algorithm with a focus on what steps need to be taken before prescribing desmopressin. METHODS: Evidence comes from existing guidelines (Google, PubMed), International Consultation on Incontinence-Research Society (ICI-RS) 2017, prescribing information and a Delphi panel (3 rounds). The International Continence Society initiated this study, the authors represent the ICI-RS, European Association of Urology, and Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU). RESULTS: Diagnostic packages: consensus on, history taking for all causalities, intake diary (fluid, food) and bladder diary, not for its duration. Pelvic (women) or rectal (men) examination, prostate-specific antigen, serum sodium check (SSC), renal function, endocrine screening: when judged necessary. Timing or empty stomach when SSC is not important. Therapeutic packages: the safe candidates for desmopressin can be phenotyped as no polydipsia, heart/kidney failure, severe leg edema or obstructive sleep apnea syndrome. Lifestyle interventions may be useful. Initiating desmopressin: risk management consensus on three clinical pictures. Follow-up of desmopressin therapy: there was consensus on SSC day 3 to 7, and at 1 month. Stop therapy if SSC is <130 mmol/L regardless of symptoms. Stop if SSC is 130 to 135 mmol/L with symptoms of hyponatremia. CONCLUSION: A summary of the nocturiapatient pathway across different medical specialists is useful in the visualization and phenotyping of patients for diagnosis and therapy. By summarizing basic knowledge of desmopressin, we aim to ease its initiation and shorten the patient journey for nocturia.
Authors: Kim Pauwaert; An-Sofie Goessaert; Lynn Ghijselings; Thomas F Monaghan; Herman Depypere; Karel Everaert Journal: Int Urogynecol J Date: 2021-01-13 Impact factor: 2.894
Authors: Jason M Lazar; Muchi Ditah Chobufo; Jeffrey P Weiss; Karel Everaert; Tine De Backer; Alan J Wein; F Charles Brunicardi; Thomas F Monaghan Journal: J Community Health Date: 2021-01-25
Authors: Thomas F Monaghan; Connelly D Miller; Christina W Agudelo; Syed N Rahman; Karel Everaert; Lori A Birder; Alan J Wein; Jeffrey P Weiss; Jason M Lazar Journal: Int Urol Nephrol Date: 2020-08-17 Impact factor: 2.370
Authors: Kara Suvada; Laura Plantinga; Camille P Vaughan; Alayne D Markland; Anna Mirk; Kathryn L Burgio; Susanne M Erni; Mohammed K Ali; Ike Okosun; Henry Young; Patricia S Goode; Theodore M Johnson Journal: Clin Ther Date: 2020-11-28 Impact factor: 3.393
Authors: Thomas F Monaghan; Kyle P Michelson; Zhan D Wu; Fred Gong; Christina W Agudelo; Christopher D George; Upeksha S Alwis; Matthew R Epstein; Pakinam Mekki; Viktor X Flores; Donald L Bliwise; Karel Everaert; Johan Vande Walle; Jeffrey P Weiss; Jason M Lazar Journal: J Clin Hypertens (Greenwich) Date: 2020-02-12 Impact factor: 3.738
Authors: Valerie Williams; Shanshan Qin; Carla DeMuro Romano; Sandy Lewis; Nicole Williams; Stuart Yarr; Kristian V Juul; Fredrik L Andersson Journal: J Clin Sleep Med Date: 2021-04-01 Impact factor: 4.062